摘要
目的:探讨肿瘤标志物糖类抗原(CA153)、糖类抗原(CA125)、癌胚抗原(CEA)联合检测在乳腺癌患者诊断中的价值。方法:收集乳腺癌患者71例(乳腺癌组),乳腺良性疾病患者58例(乳腺良性疾病组),健康查体者52例(正常对照组),采集外周血样本,运用电化学发光免疫方法(ECLIA)检测其血清CA153、CA125、CEA的含量。结果:乳腺癌组CA153、CA125、CEA含量均高于乳腺良性疾病组(P<0.05)。乳腺癌组中CA153、CA125、CEA的阳性率分别为57.7%、29.6%、23.9%,联检时阳性率为69.0%。联合检测与单项指标检测相比,敏感性明显提高。结论:联合检测血清CA153、CA125、CEA能提高乳腺癌的诊断率。
Objective： To study the value of combined assay of CA153, CA125 and CEA in the diagnosis of breast cancer. Methods： Peripheral blood samples were collected from 71 patients with breast cancer, 58 patients with breast hyperplasia, and 52 healthy volunteers. Serum levels of CA153, CA125 and CEA were determined in electro chemiluminescent immunoassay （ECLIA） method. Results： The concentration of CA153, CA125 and CEA in breast cancer group were higher than those in benign breast diseases group （P 〈 0.05 ）. The sensitivity of breast cancer by detecting the three serum markers respectively was 57.7% , 29.6% , 23.9% , which was much lower than that detected by the combined assay （69.0%）. Conclusion： The combined assay of CA153, CA125 and CEA can improve the diagnostic rate of breast cancer.
出处
《河南医学研究》
CAS
2007年第3期243-245,共3页
Henan Medical Research
